Brought to you by 
Denali scores record-breaking $217mm Series A financing
15 May 2015
Executive Summary
In the largest biopharma Series A round to date, Fidelity Biosciences, Arch Venture Partners, Flagship Ventures, the Alaska Permanent Fund (represented by Crestline Investors), sovereign wealth funds, public mutual funds, and private family offices committed $217mm in Series A financing for Denali Therapeutics Inc. (neurodegenerative diseases). Fidelity, Arch, and Flagship have representation on the start-up's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Denali scores record-breaking $217mm Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice